BioMarin Anticipates FDA Approval Of Phenoptin In Late 2007
Pricing strategies for the orphan drug are under development as BioMarin plans a 20-rep sales force expansion, firm tells “The Pink Sheet” DAILY.
Pricing strategies for the orphan drug are under development as BioMarin plans a 20-rep sales force expansion, firm tells “The Pink Sheet” DAILY.